A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Trial details
- Registry ID
- NCT06059846
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as SPR994
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)NCT06059846 | Spero Therapeutics | Phase 3 | Completed | 2025-01-27Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |